WG
VIR icon

Winton Group’s Vir Biotechnology VIR Stock Holding History

Winton Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Sell
153,491
-214,392
-58% -$2.04M 0.05% 368
2026
Q1 		$3.3M Buy
367,883
+178,577
+94% +$1.42M 0.12% 242
2025
Q4 		$1.14M Buy
189,306
+131,555
+228% +$783K 0.04% 436
2025
Q3 		$330K Buy
+57,751
New +$295K 0.01% 618
2025
Q2 		– Sell
-35,384
Closed -$229K – 1015
2025
Q1 		$229K Sell
35,384
-56,851
-62% -$505K 0.01% 608
2024
Q4 		$677K Sell
92,235
-38,730
-30% -$305K 0.05% 420
2024
Q3 		$981K Buy
130,965
+31,254
+31% +$271K 0.07% 330
2024
Q2 		$887K Buy
99,711
+18,668
+23% +$179K 0.06% 341
2024
Q1 		$821K Buy
+81,043
New +$825K 0.06% 371
2023
Q4 		– Sell
-14,943
Closed -$140K – 862
2023
Q3 		$140K Sell
14,943
-5,028
-25% -$71.7K 0.01% 699
2023
Q2 		$490K Sell
19,971
-50,017
-71% -$1.26M 0.04% 329
2023
Q1 		$1.63M Buy
69,988
+17,249
+33% +$441K 0.1% 272
2022
Q4 		$1.33M Sell
52,739
-4,903
-9% -$120K 0.09% 326
2022
Q3 		$1.11M Buy
57,642
+9,871
+21% +$251K 0.07% 376
2022
Q2 		$1.22M Buy
47,771
+32,432
+211% +$757K 0.06% 422
2022
Q1 		$395K Buy
15,339
+2,325
+18% +$69K 0.02% 745
2021
Q4 		$545K Sell
13,014
-720
-5% -$28.2K 0.03% 652
2021
Q3 		$598K Buy
13,734
+609
+5% +$26.4K 0.03% 768
2021
Q2 		$621K Buy
13,125
+1,875
+17% +$85.2K 0.03% 798
2021
Q1 		$577K Sell
11,250
-3,844
-25% -$207K 0.03% 797
2020
Q4 		$404K Sell
15,094
-37,077
-71% -$1.21M 0.03% 897
2020
Q3 		$1.79M Buy
+52,171
New +$2.25M 0.06% 581

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Winton Group's VIR Position: Q2 2026 in Review

Winton Group reduced its Vir Biotechnology (VIR) stake by 58% in Q2 2026, selling an estimated $2.04M and leaving 153,491 shares worth $1.56M. The position accounts for 0.05% of the portfolio, ranked #368.

Winton Group first reported a position in VIR in Q3 2020 and has held it in 22 quarters since. The position peaked at $3.3M in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Winton Group held 153,491 shares of Vir Biotechnology worth $1.56M as of Q2 2026.
  • Winton Group sold 214,392 Vir Biotechnology shares in Q2 2026, an estimated $2.04M.
  • Vir Biotechnology made up 0.05% of Winton Group's portfolio in Q2 2026, its #368 holding.
  • Winton Group first reported a position in Vir Biotechnology in Q3 2020 and has held it in 22 quarters since.
  • Winton Group's Vir Biotechnology position peaked at $3.3M in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.